retatrutide triple agonist obesity trial Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide for weight loss: Study

For many patients, the challenge is not just the number on the scale it is the cycle of fatigue, reduced activity, fluid retention, and discouragement that can make healthy habits feel less effective, which is why treating thyroid disease well and considering additional weight-loss support when appropriate can both matter

But Wegovy is prescribed for weight loss and weight management, and reducing alcohol consumption can help support weight loss

doi: 10.3389/fddsv.2026.1792418 Received 20 January 2026 Revised 11 March 2026 Accepted 16 March 2026 Published 10 April 2026 Volume 6 - 2026 Edited by Liang Xu, University of Kansas, United States Reviewed by Christel Menet, Confo Therapeutics, Belgium Anukriti Saran, Banasthali University, India Updates Copyright 2026 Niazi

How Does That Compare to Injectables